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ABSTRACT
Objectives: To explore whether a strategy of more
intensive antibiotic therapy leads to emergence or
prolongation of renal failure in intensive care patients.
Design: Secondary analysis from a randomised
antibiotic strategy trial (the Procalcitonin And Survival
Study). The randomised arms were conserved from
the primary trial for the main analysis.
Setting: Nine mixed surgical/medical intensive care
units across Denmark.
Participants: 1200 adult intensive care patients, 18+
years, expected to stay +24 h. Exclusion criteria:
bilirubin >40 mg/dl, triglycerides >1000 mg/dl,
increased risk from blood sampling, pregnant/breast
feeding and psychiatric patients.
Interventions: Patients were randomised to guideline-
based therapy (‘standard-exposure’ arm) or to
guideline-based therapy supplemented with antibiotic
escalation whenever procalcitonin increased on daily
measurements (‘high-exposure’ arm).
Main outcome measures: Primary end point:
estimated glomerular ﬁltration rate (eGFR) <60 ml/
min/1.73 m
2. Secondary end points: (1) delta eGFR
after starting/stopping a drug and (2) RIFLE criterion
Risk ‘R’, Injury ‘I’ and Failure ‘F’. Analysis was by
intention to treat.
Results: 28-day mortality was 31.8% and comparable
(Jensen et al, Crit Care Med 2011). A total of 3672/
7634 (48.1%) study days during follow-up in the high-
exposure versus 3016/6949 (43.4%) in the ‘standard-
exposure arm were spent with eGFR <60 ml/min/
1.73 m
2,p <0.001. In a multiple effects model, 3
piperacillin/tazobactam was identiﬁed as causing the
lowest rate of renal recovery of all antibiotics used:
1.0 ml/min/1.73 m
2/24 h while exposed to this drug
(95% CI 0.7 to 1.3 ml/min/1.73 m
2/24 h) vs
meropenem: 2.9 ml/min/1.73 m
2/24 h (2.5 to 3.3 ml/
min/1.73 m
2/24 h)); after discontinuing piperacillin/
tazobactam, the renal recovery rate increased:
2.7 ml/min/1.73 m
2/24 h (2.3 to 3.1 ml/min/1.73 m
2
/24 h)). eGFR <60 ml/min/1.73 m
2 in the two groups
at entry and at last day of follow-up was 57% versus
55% and 41% versus 39%, respectively.
Conclusions: Piperacillin/tazobactam was identiﬁed as
a cause of delayed renal recovery in critically ill
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Open Access Researchpatients. This nephrotoxicity was not observed when using other
beta-lactam antibiotics.
Trial registration: ClinicalTrials.gov identiﬁer: NCT00271752.
INTRODUCTION
Frequent complications to sepsis are organ failure,
especially respiratory failure and renal failure.
1e3 Criti-
cally ill patients are more vulnerable to organ-related
drug toxicities than less severely ill patients.
4 Rando-
mised trials assessing safety of broad-spectrum antibiotics
in intensive care settings are generally scarce, do not
have sufﬁcient statistical power for assessing organ
failure end points and do often not include deﬁned
kidney organ failure end points.
5e7 Data on renal failure
end points are also sparse in the published trials from
other patient populations, and since the absolute risk of
renal failure is low for these patients, analyses may likely
have been underpowered.
8e12
To our knowledge, randomised trials comparing ‘high
exposure’ versus ‘standard exposure to antibiotics’ and
speciﬁcally addressing whether these interventions affect
the occurrence and duration of kidney failure have not
been done before in intensive care settings.
In this secondary analysis from a randomised trial, the
Procalcitonin And Survival Study,
13 we aimed to explore
whether a strategy of more intensive antibiotic therapy
leads to adverse renal outcomes within 28 days after
recruitment.
In our study population (and often in severely infected
intensive care unit (ICU) patients), a bacterial hit has
resulted in acute onset renal failure, and this bacterial
hit (and related organ failure) is often the reason for
ICU admittance. In such situations, with the correct
treatment of the underlying infection, we expect renal
function to recover. ‘Lack of recovery’ is a non-desirable
situation, which may be very serious for the patient. We
wanted to explore this, and realising, RIFLE/AKIN
could not capture this, we have used estimated glomer-
ular ﬁltration rate (eGFR) <60 ml/min/1.73 m
2 as the
primary end point and examined this from different
angles (eGFR <60 ml/min/1.73 m
2 at day 7, days with
ml/min/1.73 m
2). The multiple effects model was built
to capture actual estimates of renal function improve-
ment using different antibiotics and adjusting for other
known or suspected causes of renal dysfunction.
Second, if renal failure was observed from the high-
exposure approach to identify one or several of the
antibiotics used in this trial as the cause of such a renal
failure.
METHODS
Trial design and participants
Procalcitonin And Survival Study is a multicentre, rand-
omised controlled trial in Denmark 2006e2009 in 1200
adult critically ill patients, expected to stay in one of the
nine participating mixed medical/surgical ICUs $24 h;
the CONSORT trial diagram is displayed in supple-
mentary ﬁgure 1. Patients were randomised 1:1 either to
treatment according to international guidelines: ‘stan-
dard-exposure arm’, or to same guidelines but supple-
mented with daily drug-escalation initiated upon
procalcitonin increases (high-exposure arm); 28-day
mortality was 31.8% and comparable between the two
groups, as reported.
13
To be eligible, patients had to be $18 years, enrolled
within 24 h of admission to the ICU and have an
expected intensive car admission length of $24 h.
Patients with known bilirubin >40 mg/dl and triglycer-
ides >1000 mg/dl (not suspensive) were not eligible
(interference with procalcitonin measurements), as were
patients who were judged to be at an increased risk from
blood sampling. The inclusion criteria were broad since
infection is frequent and often causes complications in
the patient group and to increase the external validity of
the results. The person or next of kin gave informed
consent. The study protocol was approved by the
regional ethics committees in Denmark (H-KF-272-753)
and adheres to the Helsinki declaration, revised in Seoul
2008.
In the present analyses, we explored presence and
duration of renal failure as well as change in renal
function during the observed time. End points are
deﬁned in Statistical analysis section below. Patients were
followed until day 28. The primary trial protocol and the
analysis plan are available in the online supplement.
Analysis was by intention to treat: NCT00271752.
Randomisation and masking
Randomisation was performed 1:1 using a computerised
algorithm created by the database manager (JK) with
concealed block size, pre-stratiﬁed for site of recruit-
ment, initial APACHE II and age (entered in an
encrypted screening form in a password protected
website); investigators were masked to assignment before,
but not after, randomisation. All investigators were
trained by the coordinating centre and had to register in
an investigator database. Investigators, treating physicians
and the coordinator were unaware of outcomes during
the study, as were they of all procalcitonin measurements
in the standard-exposure (control) group.
Antibiotic therapy in the two arms
The investigators enrolled participants and assigned the
high-exposure group participants to the intervention. In
the standard-exposure group, the antimicrobial treat-
ment was guided according to current clinical guide-
lines,
14 based on clinical assessment, microbiology
and radiology among other parameters, as described
elsewhere
13
In the high-exposure group, the use of antimicrobial
interventions was guided by the same clinical guidelines
as in the standard-exposure group to ascertain the best
standard of care therapy for all patients, and addition-
ally, antimicrobial interventions were initiated whenever
procalcitonin levels were not decreasing at a pre-deﬁned
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online supplement where a site-adjusted local guideline
is displayed.
Measurements, data collection and follow-up
Blood samples for biomarker measurement were made
daily in the ICU, beginning immediately after random-
isation. The assay used was the Kryptor-PCT. Organ
failure and antibiotic exposure were followed up for
until 28 days or death, as described.
13 Mortality was
followed via the National Patient Register in which all
deaths in Denmark are registered within 14 days. Good
Clinical Practice guidelines were applied. The regional
ethics board approved the protocol (H-KF-01-272-753).
Statistical analysis
The primary end point was ‘eGFR <60 ml/min/1.73 m
2’
and several analyses were made to explore this: ‘days with
eGFR <60 ml/min/1.73 m
2’, ‘risk of eGFR <60 ml/
min/1.73 m
2 on days 1e7’. Secondary end points were
(1) delta eGFR after starting/stopping a drug and (2)
RIFLE-criteria Risk ‘R’, Injury ‘I’ and Failure ‘F’ http://
www.adqi.net. Since we explored exposure of antibiotics
from baseline and forth (and not pre-ICU), in the RIFLE
deﬁnition, the baseline creatinine was used (instead of
an ideal eGFR). eGFR was calculated for every day. To
not let this be inﬂuenced by hydration status, the base-
line weight was used and thus the relation between
serum-creatinine and eGFR was a ﬁrst-degree function
for every patient. Other end points explored were ‘ever’
blood-urea level $20 mmol/l and eGFR <30.
The multiple effects eGFR ‘slope’ analyses were
adjusted for the following variables: treatment arm (high
exposure vs standard exposure), age ($65 vs <65 years),
gender, baseline APACHE II score ($20 vs <20), degree
of host response/infection at baseline (severe sepsis/
septic shock vs milder or no infection as deﬁned
15), the
eGFR at initiation of the investigated antibiotic and
ﬁnally, whether the patient at baseline was considered to
be ‘surgical’ or ‘medical’.
Comparisons were made between treatment arms
using Students t tests (for normal distributed continuous
data) and ManneWhitney U tests (for non-normally
distributed continuous data). c
2 tests and logistic
regression models were used to test categorical variables.
Time-to-event analyses comparing the high-exposure
group with the standard-exposure group were
performed using KaplaneMeier plots and Cox propor-
tional hazards models. Interactions were explored
whenever an interaction could be rationally expected
according to background literature, for the multivariate
models performed. Statistical analyses were performed
using STATA V.10.2 and SAS V.9.1. All reported p values
are two sided using a level of signiﬁcance of 0.05.
Sample size
A multivariate approach power calculation was made:
The summed squared correlations (Srho
2) to the risk of
the antibiotic drug investigated were set to 0.3. The
frequency of the end point in the standard-exposure
group was set to 20%, the sample size was set to 1200 and
the frequency of the exposure was set at 30%, which
resulted in a detection limit for OR of $1.5 (or #0.67).
RESULTS
Baseline characteristics
Nine sites included 1200 persons between 9 January
2006 and 2 June 2009. Eighty-three per cent of the
patients were assessed by the investigator to have an
infection at baseline and 81% of the patients suffered
from chronic comorbidity. Supplementary table 1 brieﬂy
summarises baseline characteristics. Mortality was
comparable between the two groups, as reported.
13
Follow-up
Follow-up for renal measures during the 28-day study
period was made on 9348 days in the standard-exposure
group of 10755 days alive and admitted to hospital
(86.9%) versus 9866 of 11380 days in the high-exposure
group (86.7%). If time after discharge from hospital
(where no serum-creatinine values were determined)
until day 28 was included, the percentage of days with
assessment of renal failure was 71.2% (9348/
13130 days) versus 73.8% (9866/13377 days).
Use of antibiotics
The antibiotics used most while admitted to the ICU
were piperacillin/tazobactam, cefuroxime, meropenem
and ciproﬂoxacin, and there was a substantial higher use
of piperacillin/tazobactam and ciproﬂoxacin in the
high-exposure arm (supplementary table 2). Vanco-
mycin was used to a lesser extent in both groups, and
aminoglycosides and colistin were used rarely in both
groups.
The median length of an antibiotic course was
prolonged using the high-exposure algorithm (6 days
(IQR 3e11) versus 4 days (IQR 3e10), p¼0.004).
Renal failure in the originally randomised study arms
The percentage of days within days 1e28 with eGFR
#60 ml/min/1.73 m
2 was 48% in the high-exposure arm
versus 43% in the standard-exposure arm, p<0.0001.
Results in table 1 are eGFR values, based on actual
measured S-creatinine values; results regarding days with
eGFR were comparable if using the ‘last observation
carried forward’ approach (not shown). RIFLE-criterion
‘R’ occurred more often within days 1e28 in the high-
exposure arm than the standard-exposure arm: 209
patients versus 170 patients, p¼0.02, as did blood urea
levels exceeding 20 mmol/l: 253 (43.4%) versus 217
(37.4%), p¼0.04.
The frequency of renal failure on the last day of
follow-up was comparable between the arms (table 2),
underlining that the results depicted in table 1 reﬂect
a temporary extension of duration of renal failure in the
high-exposure group and furthermore that this observa-
tion is not explained by premature discharge of renally
incompetent patients in the standard-exposure arm.
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Comparison of the eGFR of all patients (both study
arms) for the ﬁrst 10 days after starting on the most
frequently used beta-lactam antibiotics showed that the
slowest recovery of renal function was observed in
patients on piperacillin/tazobactam as compared with
patients on meropenem or cefuroxim (ﬁgure 1). A
multiple effects model investigating the eGFR regression
coefﬁcient (‘increase in eGFR’) per day on these drugs
conﬁrmed that renal recovery was lowest in patients on
piperacillin/tazobactam (table 3). Of note, renal
recovery seems to be low in patients exposed to cefur-
oxim, but as displayed in ﬁgure 1, this drug is given to
patients with a relatively normal renal function (leaving
few possibilities for ‘recovery’).
For the ﬁrst 5 days following discontinuation of these
drugs, adjusting for the same variables, eGFR increased
at the highest rate in patients receiving piperacillin/
tazobactam (table 3).
The frequency of eGFR<60 ml/min/1.73 m
2 on day 7
(or at death or last follow-up day) in the trial was 523/
1200¼43.6%. This end point was investigated in
a forward censored (p<0.1) logistic regression. Use of
piperacillin/tazobactam and other frequently used beta-
lactam drugs for at least 3 days within these ﬁrst 7 days as
well as known and suspected predictors of renal failure
were explored in a multivariable logistic regression
analysis. Five independent predictors of renal failure on
day 7 were identiﬁed: age above 65 years, APACHE II
score >20, Charlson’s comorbidity score $2, eGFR at
baseline and use of piperacillin/tazobactam for at least
3 days within the ﬁrst 7 days (table 4). Excluding all
patients who died within the ﬁrst 7 days, excluding all
patients with invasive fungal infection on days 1e28,
combining the beta-lactam exposure with exposure to
ﬂour-quinolone exposure (data not shown) or adding
‘Alert-procalcitonin’ at baseline as a variable did not
alter the signal (data not shown). To validate the end
Table 1 Prevalence and duration of kidney organ failure (‘standard-exposure’ group vs ‘high-exposure’ group)
Standard-exposure
group (N[596)
High-exposure
group (N[604) p Value
eGFR*: number of days (% of days from days 1 to 28 with values):
Moderatelyeseverely impaired (eGFR: #60 ml/min/1.73 m
2) 3016 (43.4) 3672 (48.1) <0.0001
Severely impaired (eGFR #30 ml/min/1.73 m
2) 1445 (20.8) 1910 (25.0) <0.0001
Severely impaired (eGFR #30 ml/min/1.73 m
2),
days from days 1 to 14
984 (20.0) 1253 (23.5) <0.0001
‘RIFLE’ criteria, number of patients (%) within days 1e28
’R’ reached 170 (28.5) 209 (34.6) 0.02
‘I’ reached 75 (12.6) 92 (15.2) 0.19
‘F’ reached 121 (20.3) 150 (24.8) 0.06
‘R’ or death 298 (50.0) 327 (54.1) 0.15
‘I’ or death 234 (39.3) 252 (41.7) 0.39
‘F’ or death 270 (45.3) 287 (47.5) 0.44
Urea
Patients with a urea level ever $20 mmol/l (days 1e28), n (%) 217 (37.4) 253 (43.4) 0.04
*eGFR was assessed using the Cockcroft and Gault method (Ref: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum
creatinine. Nephron 1976;16:31e41). Actual measured creatinin values were used. If using the ‘last observation carried forward’ approach
regarding creatinin measurement to take into account that patients who died in renal failure should be counted as such did not change the signal
or the statistics of these analyses. ‘R’: Risk, ‘I’: Injury, ‘F’: Failure. Presence of renal failure according to ‘RIFLE’ was assessed using the
guidelines developed by the acute dialysis quality initiative (http://www.adqi.net).
eGFR, estimated glomerular ﬁltration rate.
Table 2 Prevalence of kidney organ failure on the last day of follow-up (‘standard-exposure’ group vs ‘high-exposure’ group)
Standard-exposure
group
High-exposure
group p Value
Survivors and patients who had last creatinine measured
>24 h before death
N¼432 N¼438
Renal failure (*eGFR: #60 ml/min/1.73 m
2) 119 (27.6%) 137 (31.3%) 0.23
Patients who died (with last creatinine measured within
24 h before death)
N¼150 N¼145
Renal failure (eGFR: #60 ml/min/1.73 m
2) 105 (70.0%) 99 (68.3%) 0.83
All patients with creatinine measurements N¼582 N¼583
Renal failure (eGFR: #60 ml/min/1.73 m
2) 224 (38.5%) 236 (40.5%) 0.51
*eGFR was assessed using the Cockcroft and Gault method (Ref: Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum
creatinine. Nephron 1976;16:31e41). Actual measured creatinin values were used.
eGFR, estimated glomerular ﬁltration rate.
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done; eGFR <60 ml/min/1.73 m
2 on day 7 was found to
be the strongest predictor of ‘all-cause mortality days
7e28’ of all tested variables (table T1, supplementary
material).
DISCUSSION
Principal ﬁndings
We observed that the duration of renal failure is
prolonged in critically ill patients randomised to receive
high exposure to broad-spectrum antibiotics and esca-
lated diagnostic work-up according to a biomarker-
strategy compared with patients randomised to receive
standard care according to guidelines regarding use of
antibiotics and diagnostics. This difference in renal
function was mainly conﬁned to a prolongation of
existing renal dysfunction since there was only
a moderate, although signiﬁcant, difference in de novo
acute renal failure.
To our knowledge, this study provides the ﬁrst clinical
report to inform this critical issue within ICU medicine.
First, the study was a randomised, good clinical practice
controlled trial with a high sample size for comparison of
organ failure, and the patients’ baseline characteristics
in general and speciﬁcally regarding renal parameters
were comparable. Second, the rate of follow-up,
although not complete for the entire period, was high
and equal among the groups and the rate of renal failure
on the last day of follow-up in the two groups was
comparable. Thus, the observed increased risk of
persistent renal failure in the high-exposure group is
attributable to this intervention in some way.
The intervention consisted of an increased number of
culture samples, a proposed initiative to do further
diagnostic imaging (no observed difference) and a rapid
and aggressive antibiotic escalation with certain drugs,
which was documented to be of substantial extent
(supplementary table 2). As a moderate increase in
microbiologic sampling would not cause renal failure
and since there was no observed increase in diagnostic
imaging, these interventions seems implausible reasons
to explain the observations depicted in table 1.
This leaves us with the documented escalation in use
of piperacillin/tazobactam and ciproﬂoxacin as possible
explanations. Before concluding that the observed renal
dysfunction was caused directly by one (or both) of
these drugs, we wanted to exclude the possibility that
the results had appeared because of a derived effect
of an increase in fungal infections. Fungal infections
have been linked to broad-spectrum antibiotics,
16 and
renal failure is a well-known complication to some
Figure 1 Estimated glomerular ﬁltration rate (eGFR) during
10 days on cefuroxim, piperacillin/tazobactam and
meropenem. Difference between eGFR in patients receiving
piperacillin/tazobactam versus meropenem: day 1 (p¼0.78),
day 2 (p¼0.18), day 3 (p¼0.09), day 4 (p¼0.008), day 5
(p¼0.001), day 6 (p¼0.001), day 7 (p¼0.0004), day 8
(p¼0.005), day 9 (p¼0.006) and day 10 (p¼0.02).
Table 3 Multiple effects models investigating eGFR changes after starting and stopping beta-lactam antibiotics
Variable
Unadjusted analysis Multivariable analysis
Regression
coefﬁcient (95% CI) p Value
Regression
coefﬁcient (95% CI) p Value
After starting the drug
Piperacillin/
tazobactam
Per day more on
piperacillin/tazobactam
1.39 (1.17 to 1.60) <0.0001 0.99 (0.71 to 1.27) <0.0001
Meropenem Per day more on meropenem 2.74 (2.39 to 3.09) <0.0001 2.86 (2.45 to 3.28) <0.0001
Cefuroxim Per day more on cefuroxim 1.91 (1.67 to 2.16) <0.0001 1.27 (0.90 to 1.64) <0.0001
After stopping the drug
Piperacillin/
tazobactam
Per day after stopping
piperacillin/tazobactam
2.79 (2.35 to 3.24) <0.0001 2.70 (2.26 to 3.14) <0.0001
Meropenem Per day after stopping
meropenem
0.20 ( 0.51 to 0.91) 0.59 0.17 ( 0.52 to 0.86) 0.63
Cefuroxim Per day after stopping
cefuroxim
0.13 ( 0.25 to 0.50) 0.51 0.01 ( 0.35 to 0.37) 0.96
All multivariable analyses were adjusted for: treatment arm (‘low exposure’ vs ‘high exposure’), gender, age ($65 vs <65 years), APACHE II
score ($20 vs <20), clinically judged infection (severe sepsis/septic shock vs milder or no infection), patient category (surgical vs medical) and
eGFR level at administration of the antibiotic (1: <30 ml/min/1.73 m
2,2 :3 1 e60 ml/min/1.73 m
2,3 :>60 ml/min/1.73 m
2).
eGFR, estimated glomerular ﬁltration rate.
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17 However, excluding all patients with
invasive fungal infections did not alter the results.
Based on these results and after having excluded other
potential explanations, we realised that nephrotoxicity
from piperacillin/tazobactam and/or ciproﬂoxacin was
the most plausible explanation of the observed renal
dysfunction. To further substantiate this, several analyses
were conducted. A multiple effects model was built to
examine the GFR in the days after administration of
different frequently used drugs. This model included
the ﬁve most often administered antibiotics, including
piperacillin/tazobactam, meropenem, cefuroxim,
ciproﬂoxacin and vancomycin along with other known
and suspected causes of renal failure. In this model, the
use of piperacillin/tazobactam was associated with
a striking low rate of GFR improvement compared with
the other drugs investigated. Intriguingly, this adverse
effect appears to be reversible since patients in whom
piperacillin/tazobactam was discontinued had the fastest
improvement in renal function as compared with
patients on other antibiotic courses. Several sensitivity
analyses were performed with ﬁndings consistent with
this observation.
Comparison with other studies
Although clinical evidence regarding renal failure
according to use of piperacillin/tazobactam in ICU
patients has been limited, the inﬂuence of piperacillin
on renal function has been investigated in healthy
volunteers in laboratory experiments. In a cross-over
experiment, the inﬂuence on drug clearance from
concurrent administration of piperacillin and ﬂuclox-
acillin was estimated.
18 The authors observed that
ﬂucloxacillin clearance was reduced to 45% (90% CI 40
to 50%) when piperacillin was administered simulta-
neously, whereas piperacillin clearance was unaffected
by concurrent ﬂucloxacillin administration. Timee
clearance slope modelling identiﬁed competitive
inhibition of renal tubular secretion as the most
likely explanation. Piperacillin-induced reduction of
imipenem clearance
19 and of tazobactam clearance has
also been found,
20 and a high correlation between
creatinin clearance and piperacillin clearance has been
documented,
21 and thus, it is plausible that piperacillin
speciﬁcally causes nephrotoxicity.
Additionally, the published randomised trials
comparing piperacillin/tazobactam with other beta-
lactam drugs in ICU settings are scarce, underpowered
for assessment of renal failure end points and do
generally not address renal end points.
5e7 Trials from
other settings: haematological patients, diabetes patients
and surgical settings do generally not investigate renal
failure end points, and in the few (non-ICU) trials that
do report kidney end points, the total frequency of these
makes the power to avoid type II error very low (diagram
D2, online supplement).
Strengths and weaknesses of the study
Although our study is performed on analyses from
a large, randomised, good clinical practice controlled
trial with a stringent methodology and a high level of
follow-up, there are limitations that deserve mentioning:
Table 4 Multivariable logistic regression: beta-lactam antibiotics and other risk variables versus binary end point eGFR
<60 ml/min/1.73 m
2 on day 7
Unadjusted analysis Multivariable analysis
Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value
Other variables
Age ($65 vs <65 years) 2.36 (1.86 to 3.00) <0.0001 1.85 (1.31 to 2.60) <0.0001
APACHE II score ($20 vs <20) 2.49 (1.90 to 3.25) <0.0001 1.64 (1.12 to 2.41) 0.01
Severe sepsis/septic shock versus
milder or no infection
2.02 (1.59 to 2.56) <0.0001 1.16 (0.82 to 1.66) 0.40
Autoimmune disease (Y vs N) 1.31 (0.73 to 2.33) 0.36 NI e
Cancer (Y vs N) 1.26 (0.88 to 1.79) 0.21 NI e
Charlson score ($2v s<2) 1.72 (1.35 to 2.18) <0.0001 1.70 (1.21 to 2.40) 0.002
Surgical (Y vs N) 1.16 (0.90 to 1.50) 0.24 NI e
Body mass index ($25 vs <25) 1.57 (1.17 to 2.12) 0.003 1.19 (0.78 to 1.82) 0.41
Gender (male vs female) 1.25 (0.99 to 1.57) 0.06 1.28 (0.92 to 1.78) 0.14
eGFR level at baseline
>60 ml/min/1.73 m
2 Ref e Ref e
31e60 ml/min/1.73 m
2 14.6 (10.2 to 21.0) <0.0001 11.7 (8.0 to 17.0) <0.0001
<30 ml/min/1.73 m
2 81.1 (51.2 to 128.5) <0.0001 65.9 (40.7 to 106.6) <0.0001
Beta-lactam antibiotics
Piperacillin/tazobactam ($3v s<3 days)* 2.32 (1.82 to 2.96) <0.0001 1.70 (1.18 to 2.43) 0.004
Meropenem ($3v s<3 days)* 0.99 (0.71 to 1.37) 0.94 NI e
Cefuroxim ($3v s<3 days)* 0.73 (0.57 to 0.94) 0.01 1.24 (0.85 to 1.80) 0.26
All variables entered in the multivariable analysis were adjusted for the other variables in this model.
*All beta-lactam drug exposures are 3 vs <3 days. eGFR was measured on day 7. If a day 7 measurement was not available, the last
measurement before this day was used. All variables with a p value <0.2 were included in the multivariable model.
eGFR, estimated glomerular ﬁltration rate; N, no; NI, not included; Y, yes.
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complete, although we followed patients for all blood
samples done in (1) the hospital, at which they were
initially recruited and (2) other hospitals in Denmark,
where we had electronic access to blood samples.
However, patients who continued to suffer from renal
failure when discharged from hospital were out of reach
for follow-up for their renal function. Of note, the
fraction of patients with remaining renal failure at time
of discharge was comparable between the two groups
(table 2), and hence, it is unlikely that this lack of ability
to ascertain renal outcome contributed to our main
ﬁndings.
Second, eGFR may not be an accurate measure of
creatinine clearance, as recently documented by Martin
et al.
22 However, even though this measure is not accu-
rate to describe the creatinine clearance, changes in
eGFR reﬂect changes in renal function, as validated, and
is closely correlated to outcome.
23 Additionally, since
hydration can be a source of error, we used the baseline
weight in the eGFR equation. Additionally, we found
that eGFR <60 ml/min/1.73 m
2 on day 7 is a strong
independent predictor of mortality.
Third, the RIFLE criteria used as secondary end point
measures are not suitable to detect renal failure from
baseline and forth since the reference is deﬁned as the
pre-morbid creatinine. Hence, renal failure caused by
exposure to antibiotics beginning at baseline will not
necessarily be captured using these criteria. This was the
reason for not using these as primary end points.
Forth, the study was a post hoc analysis using a previ-
ously published trial as material. We have tried to
compensate for this by writing a detailed analysis plan
based on the hypotheses, we wanted to test, before
analysis. Fifth, although the sample size was relatively
large compared with most other randomised trials in this
setting, the sample size for these secondary analyses were
based on the assumption of 25% renal failure in the
standard-exposure group and a RR of 1.25 in the high-
exposure group. The observed numbers were 21% and
1.22 of which calls for a slightly higher sample size.
However, the sample size needed to show the differences
observed in the multivariable analyses was far smaller,
and since these analyses conﬁrmed the main ﬁndings,
we do not think the results are due to chance.
In this trial, for the ﬁrst time ever to our knowledge,
random allocation to high exposure to broad-spectrum
antibiotics in the ICU has been systematically applied
according to a systematic algorithm and this resulted in
prolongation of renal failure. The results were
conﬁrmed when excluding patients with fungal infec-
tions, and a multiple effects model revealed a particu-
larly low renal recovery in patients while piperacillin/
tazobactam was administered and a remarkable recovery
when discontinuing this drug, a ﬁnding that was speciﬁc
for this drug. Several other crude and adjusted models
likewise conﬁrmed the ﬁndings. Finally, the results from
this trial are supported by human experimental studies.
CONCLUSIONS
In conclusion, the use of piperacillin/tazobactam caused
a delayed renal recovery in critically ill patients and renal
function improved after discontinuation of the drug.
However, the study is not designed to investigate de novo
emergence of renal failure since the lowest renal func-
tion is at baseline in most patients. The study was not
designed to establish whether the use of piperacillin/
tazobactam or other of the interventional drugs, in some
cases, cause persistent renal failure, and thus, further
research to explore this is warranted. We think this
impact on renal function is more likely caused by adat
least partially reversibledtoxic effect on the renal tubule
than by a lack of effect towards the infection since this
drug is independently associated with a high chance of
survival in other infected populations,
8 and we must
emphasise that our ﬁndings are strictly conﬁned to
critically ill patients.
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APPENDIX 1
The members of the Procalcitonin And Survival Study (PASS) study
group are as follows: Central Coordinating Center: J U Jensen, B
Lundgren, J Grarup, M L Jakobsen, S S Reilev, M Kofoed-Djursner, J
D Lundgren; Regional Coordinating Centres: Hvidovre: J Løken, M
Steensen; Gentofte: T Mohr, K Thornberg, K Thormar; Hillerød: L Hein,
M Bestle; Glostrup: D Strange, A Ø Lauritsen; Herlev: H Tousi, P Søe-
Jensen; Roskilde: N Reiter, N E Drenck; Skejby: M H Andersen, P
Fjeldborg; A ˚rhus: K M Larsen; Data Management & Statistical Centre:
Z Fox, J Kjær, D Kristensen; Procalcitonin Analysis & Logistics Centre:
J U Jensen, B Lundgren, M B Rasmussen, C S v Hallas, M Zacho, J
Iversen, T Leerbeck, M Jeppesen, K S Hansen, K B Jensen; Data and
Safety Monitoring Board: H Masur (Chair), J Chastre, H Schønheyder,
C Pedersen; Clinical Microbiology Management: B Lundgren, J D
Knudsen, A Friis-Møller, K Schønning, A Lester, H Westh, G Lisby, J K
Møller, B Bruun, J J Christensen, C Østergaard, M Arpi, K Astvad, M D
Bartels, J Engberg, H Fjeldsøe-Nielsen, U S Jensen; PASS Site
Clinical Investigators (numbers of recruited persons are in paren-
theses): Glostrup (290): L Hein, T Mohr, D G Strange, P L Petersen, A
Ø Lauritsen, S Hougaard, T Mantoni, L Nebrich, A Bendtsen, L H
Andersen, F Bærentzen, Andreas Eversbusch, B Bømler, R Martuse-
vicius, T Nielsen. P M Ba ˚dstøløkken, C Maschmann, U Grevstad, P
Hallas, A Lindhardt, T Galle, K Graeser, E Hohwu-Christensen, P
Gregersen, H C Boesen, L M Pedersen, K Thiesen, L C Hallengreen, I
Rye, J Cordtz, K R Madsen, P R C Kirkegaard, L Findsen, L H Nielsen,
D H Pedersen, J H Andersen, C Albrechtsen, A Jacobsen, T Jansen, A
G Jensen, H H Jørgensen, M Vazin; Gentofte (209): L Lipsius, K
Thornberg, J Nielsen, K Thormar, M Skielboe, B Thage, C Thoft, M
Uldbjerg, E Anderlo, M Engsig, F Hani, R B Jacobsen. L Mulla, U
Skram; Herlev (154): H Tousi, P Søe-Jensen, T Waldau, T Faber, B
Andersen, I Gillesberg, A Christensen, C Hartmann, R Albret, D S
Dinesen, K Gani, M Ibsen; Hvidovre (148): J Løken, M Steensen, J A
Petersen, P Carl, E Gade, D Solevad, C Heiring, M Jørgensen, K
Ekelund, A Afshari, N Hammer, M Bitsch, J S Hansen, C Wamberg, T
D Clausen, R Winkel, J Huusom, D L Buck, U Grevstad, E Aasvang, K
Lenz, P Mellado, H Karacan, J Hidesta ˚l, J Høgagard, J Højbjerg, J
Højlund, M Johansen, S Strande; Hillerød (138): M Bestle, S Hestad, M
Østergaard, N Wesche, S A Nielsen, H Christensen, H Blom, C H
Jensen K Nielsen, N G Holler, K A Jeppesen; A ˚rhus-Skejby (94): M H
Andersen, P Fjeldborg, A Vestergaard, O Viborg, C D Rossau;
Roskilde (90): N Reiter, M Glæemose, M B Wrane ´r, C B Thomsen, B
Rasmussen, C Lund-Rasmussen, B Bech, K Bjerregaard, L Spliid, L L
W Nielsen, N E Drenck; A ˚rhus-Centre (63): K M Larsen, M Goldinger,
D Illum, C Jessen, A Christiansen, A Berg, T Elkmann, J A K Pedersen,
M Simonsen; Bispebjerg (14) H Joensen, H Alstrøm, C Svane, A
Engquist.
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